S

Sanofi

Global pharma company; vaccines and R&D

Principal Biostatistician - Vax

Full-TimeDeadline 11/30/26
No salary listed
Senior, Expert
Master's, PhD
Hyderabad, Telangana, India
In Person
Biology & BiotechQuantitative Biology & Biostatistics

About the job

Requirements
  • At least eight years of experience in clinical Biostatistics and Programming research.
  • Experience acting end to end as a Study Biostatistician, including non-standard sample size calculations, statistical sections of protocols, randomization setup with a vendor, Statistical Analysis Plans, analyses, study reports, and publications.
  • Experience leading programmers through electronic-submission statistical activities such as Integrated Summary of Safety, Integrated Summary of Efficacy, and Integrated Summary of Immunogenicity.
  • Experience performing complex exploratory statistical analyses without written specifications.
  • Successful experience leading several concurrent studies or projects, including programming experience in SAS and R.
  • Knowledge of CDISC, including SDTM, ADaM, SEND, specifications, P21, define.xml, and Reviewer's Guides.
  • Excellent understanding of clinical-trial processes and their interfaces and interdependencies with other functions.
  • Interpersonal, teamwork, technical, and leadership skills.
  • Strong project-management skills.
  • Ability to organize multiple work assignments for a team and establish priorities.
  • Understanding of and ability to contribute to resourcing-strategy implementation and capacity and capability development.
  • Highly effective oral and written English communication skills.
Responsibilities
  • Support clinical study design, including concept protocol development, study setup, conduct, and reporting.
  • Develop statistical sections of protocols, including statistical methodology and sample-size calculations; ensure protocols are statistically sound; contribute to randomization specifications and setup; develop Statistical Analysis Plans; plan and execute statistical data surveillance; perform data analysis; contribute to interpretation of results; ensure the statistical integrity of clinical study reports; and deliver Transparency and Disclosure materials.
  • Develop Integrated Analysis Plans for safety or immunology summaries, conduct related analyses in collaboration with programming, and deliver outputs for submission Core Technical Dossiers.
  • Work with the programming team to provide definitions, documentation, and review of derived variables and quality-control plans; perform or coordinate production of statistical analyses and CDISC-compliant data packages ready for submission.
  • Propose, prepare, and perform complex exploratory and ad hoc data analyses relevant to study or project objectives and Health Authority questions.
  • Provide statistical insight into interpretation of results in line with other sponsored studies and competition results, and present and explain the selected methodology and its consequences for interpretation and decisions.
  • Collaborate productively with functions in aligned study teams and safety-monitoring teams, and communicate with senior leadership.
  • Represent Statistics in scientific or technology working groups and cross-functional initiatives.
Desired Qualifications
  • A PhD or Master's degree in Statistics, Mathematics, or related health sciences, or equivalent experience.
  • Three to five years of experience in Vaccines, including trial designs, endpoints, and statistical methods.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Yahoo Finance
Oct 30th, 2026
Sanofi shares jump 6% as it raises 2026 outlook and signals appetite for bigger deals

Sanofi shares jumped nearly 6% on Friday after the drugmaker raised its 2026 outlook and said it is open to larger deals. The company now expects sales to grow in the low teens this year, with business earnings per share up in the mid-teens at constant exchange rates. Third-quarter sales rose 14.3% to 14.44 billion, and operating income was 5.43 billion. Dupixent remained the main growth driver, with sales up 34.8% to 5.7 billion. New medicines added 1.4 billion. Chief financial officer Francois Roger said Sanofi could consider deals above its typical $2 billion to $5 billion range. The company continues to focus on immunology, rare diseases, and vaccines.

Yahoo Finance
Oct 30th, 2026
Sanofi lifts 2026 guidance as Q3 sales rise 14.3% to $15.6B on Dupixent strength

Sanofi reported third-quarter sales of €14.4 billion, up 14.3% at constant exchange rates, and raised its 2026 outlook. Business operating income rose 19.7%, while business EPS increased 19.6%. The company now expects 2026 sales growth of 13% to 15% and business EPS growth of 15% to 17%. Dupixent sales hit €5.7 billion, with more than 1.5 million patients treated worldwide. Sanofi still targets Dupixent sales of €25 billion by 2030. Sanofi is focusing on immunology, rare diseases, and vaccines. It discontinued two development programmes and expanded its Regeneron alliance to four next-generation antibodies. Planned divestments are expected to cut 2027 sales by about €1.3 billion.

Yahoo Finance
Oct 30th, 2026
Sanofi raises 2026 guidance after Q3 sales rise 14.3% to $15.6B, with Dupixent up 34.8%

Sanofi raised its 2026 guidance after third-quarter sales grew 14.3% at constant exchange rates (CER) to €14,444 million. Business earnings per share (EPS) rose 19.6% at CER to €3.55. The company now expects full-year sales to grow by a low-teens percentage at CER, and business EPS by a mid-teens percentage. Dupixent sales rose 34.8% to €5.7 billion. Sales of newly launched drugs, including ALTUVIIIO, Ayvakit, and Rezurock, climbed 31.4% to €1.4 billion. Vaccines sales fell 6.6% to €3.2 billion. Selling and general expenses fell 0.9% to €2.3 billion. Research and development spending was broadly stable at €1.8 billion. Chief executive officer Belén Garijo said the company's priority is to protect earnings when Dupixent loses exclusivity.

PR Newswire
Oct 29th, 2026
Novavax earns $125M milestone as Sanofi starts Phase 3 flu-COVID vaccine trial

Novavax has earned a $125 million milestone payment after Sanofi dosed the fifth patient in a Phase 3 trial of an influenza-COVID-19 combination vaccine in Europe. The trial tests the safety and immune response of Novavax's COVID-19 vaccine, Nuvaxovid, combined with Sanofi's Efluelda/Fluzone High-Dose flu vaccine in adults aged 60 and older. Novavax could receive a $75 million milestone once manufacturing technology transfer is completed, expected in mid-2027. It is also eligible for $225 million upon a US launch of a combination vaccine, plus royalties on Sanofi sales. "To date, the partnership has generated over $1 billion in revenue for Novavax," said chief executive officer John C. Jacobs.

Yahoo Finance
Oct 29th, 2026
Sanofi brings non-mRNA COVID-19 vaccine Nuvaxovid to 10 provinces and Yukon for 2026-2027

Sanofi Canada said its protein-based, non-mRNA COVID-19 vaccine, Nuvaxovid, will be available in all 10 provinces and the Yukon for the 2026-2027 respiratory season. It will be offered through provincial respiratory programs and most private insurers. The vaccine is already available in British Columbia, Alberta, and Quebec. In Ontario, it should reach healthcare provider offices and public health units from the week of October 26, 2026, with pharmacies to follow. Nuvaxovid is approved for people aged 12 and older. Sanofi says pivotal phase 3 trials showed about 90% efficacy against symptomatic COVID-19. Nearly 77% of Canadian adults skipped a COVID-19 vaccine last season, according to the company. Sanofi hopes more choice will encourage uptake.